Figure 4.
Pharmacokinetics of VCAMelid, BiVCAMelid, and VCAM/ALB8 in TNF-α injected mice. (a) Blood, (b) Spleen, and (c) Brain concentration vs time profile. PK studies were performed after injection of equimolar doses of monovalent (VCAMelid, 5 μg), bivalent (BiVCAMelid, 10 μg) and bispecific (VCAM/ALB8, 10 μg) nanobodies.